Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$0.52 USD
+0.01 (2.94%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.52 0.00 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGMO 0.52 +0.01(2.94%)
Will SGMO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGMO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMO
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
SGMO: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy
FDA Accepts Pfizer's (PFE) Hemophilia B Gene Therapy Filing
Strength Seen in Pharming Group N.V. Sponsored ADR (PHAR): Can Its 5.2% Jump Turn into More Strength?
Other News for SGMO
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Biotech Roundtable: Who will bring the next CRISPR drug to market?
12 Health Care Stocks Moving In Friday's Intraday Session
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall